With its potential to expand the horizons of what’s possible for patients, CRISPR is the new darling of biotech. Reaching an important milestone in 2023 with the FDA approval of a sickle cell treatment using CRISPR, the technology is poised to break new barriers for treating patients in the near future. In this episode we talk with two companies working together on the next generation of CRISPR: editing cells within the body.  We discuss the progress and the challenge in making this breakthrough a reality. 

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

Biotech companies are addressing climate change through innovation—from carbon neutral facilities to agricultural innovations to reduce greenhouse gas emissions. BIO was on the ground at the COP28 UN Climate Change Conference in Dubai to deliver the message that biotech is climate tech.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

More than half of U.S. households include pets, but there has been a lack of medical treatments developed specifically for small animals. Biotech companies are working to change that with new treatment options that both borrow from and, potentially, advance human health discoveries.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

The gut microbiome, which consists of trillions of bacteria, viruses, and fungi, plays a crucial role in our health. However, there is still much to learn about this complex ecosystem. On this episode we talk with experts who tell us where the science is—how much we know, and how much we don’t. Two companies, Bloom Science and Seres Therapeutics, are leveraging the microbiome to develop new therapeutics. The potential of the microbiome is vast, and further research and technological advancements will continue to unlock its benefits.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

2023 ended with an exciting biotech breakthrough for sickle cell patients. A gene-editing therapy using the revolutionary CRISPR technology provides new hope and options for the nearly 100,000 Americans with sickle cell disease. In this episode, we talk with the company behind one of the life-changing therapies, CASGEVY, and speak with two advocates for sickle cell patients. 

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

Bradley Burnam woke up one morning, looked in the mirror and found one ear twice it’s normal size and his face swollen and discolored. He would spend the next several years in and out of the hospital fighting a relentless infection that would not respond to available treatments. The experience took him from patient to mad scientist, to biotech company founder. In this episode, Bradley takes us through his desperate journey to find a cure. We also talk with the leader of an organization helping to get more antimicrobials to the marketplace.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

Innovative companies are using synthetic biology to engineer organisms and create new materials that could transform every sector of our economy, from health care to food and energy production. Those companies say we’ve entered a synbio revolution, and it holds potential to improve the health of people and our planet. In this episode, we talk with three synbio experts about how this convergence of genetic engineering, computer science and other scientific disciplines is making our world more sustainable. 

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

For biotech companies, the valley of death describes the difficult path from initial discovery to FDA approval and commercialization. It's a treacherous journey—one that even promising innovations often don't complete. Adequate funding, regulatory hurdles and the immense complexity of the biotech landscape are among the never-ending challenges faced by early stage biotechs. In this episode we talk with two biotech executives about what it’s like to struggle and survive in this rough-and-tumble industry.  

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

The biotech industry offers unique opportunities for women to advance as executives and entrepreneurs. There are headwinds, however, including unequal access to venture capital. In this episode, we talk with three executives who are part of a wave of women-led companies in biotech. Our guests speak to why women’s leadership matters and the barriers that remain to breaking the glass ceiling. They also tell us about a new networking initiative—the biotech sisterhood—to catalyze women’s success in corporate leadership and mentor the next generation of women executives.  

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/

Bees and other pollinators are critical to our survival, with one out of every three bites of food we eat depending on pollination to produce. That’s why reports of a decline in bee populations and rising threats from pests, viruses and environmental pressures, including climate change, are alarming.

In this episode we talk with an expert on bees and other pollinators about how bees are doing and why it’s important to save them. We also talk with two biotech leaders whose companies are working to improve bee health through development of innovative treatments for some of the worst threats faced by bees.

Follow us on LinkedIn, X, Facebook and Instagram. 

Visit us at https://www.bio.org/